Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups

Following the success of immune checkpoint blockers (ICBs) in different cancer types, a large number of studies are currently investigating ICBs in patients with hepatocellular carcinoma (HCC), alone or in combination with other treatments. Both nivolumab and pembrolizumab, as well as the combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinter, Matthias, Scheiner, Bernhard, Peck-Radosavljevic, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Recent Advances in Clinical Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788203/
https://www.ncbi.nlm.nih.gov/pubmed/32747413
http://dx.doi.org/10.1136/gutjnl-2020-321702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788203/
https://www.ncbi.nlm.nih.gov/pubmed/32747413
http://dx.doi.org/10.1136/gutjnl-2020-321702

Ejemplares similares